The Canadian Task Force on Preventive Health Care (task force) recommends “risk assessment–first” screening to prevent fragility fractures in females aged ≥ 65 years, as follows (conditional recommendation; low-certainty evidence):

  • Apply the Canadian clinical FRAX* (without BMD). Use the 10-year absolute risk of major osteoporotic fracture to facilitate shared decision-making about the possible benefits and harms of preventive pharmacotherapy.
  • After discussion, if preventive pharmacotherapy is considered, request BMD measurement using DXA of the femoral neck. Then re-estimate fracture risk by adding the BMD T-score into FRAX.

We recommend against screening females aged 40–64 years and males aged ≥ 40 years to prevent fragility fractures (strong recommendation; very low-certainty evidence).

By using this site you acknowledge that you have read, understand, and agree to be bound by our terms of use and privacy policy. All content and tools are for educational use only, are not meant to be a substitute for professional advice and should not be used for medical diagnosis and/or medical treatment.